Thorne is one of the most trusted names in the premium supplements industry — the brand that professional athletes, elite sports teams, and healthcare practitioners reach for when the formula absolutely has to be right.
But ownership of Thorne has been one of the most eventful stories in the entire supplement industry in recent years. And just weeks ago, on August 4, 2026, a deal was announced that may be the biggest moment in the brand’s entire 42-year history.
What Is Thorne?
Thorne is an American premium supplement manufacturer founded in 1984 and headquartered in Summerville, South Carolina. The company produces science-backed vitamins, minerals, supplements, and health tests, with a strong emphasis on ingredient purity, third-party testing, and practitioner-channel trust.
Thorne is trusted by tens of thousands of healthcare professionals, thousands of professional athletes, over 100 professional sports teams, and multiple U.S. Olympic teams.
Its products — including bestsellers like Magnesium Glycinate, Basic Nutrients, and Ginseng Plus — are manufactured at the company’s own facility in South Carolina, maintaining a vertically integrated model that sets it apart from most supplement brands that outsource production.
Who Owns Thorne Right Now in 2026?
Here is the most current and accurate answer: Thorne is currently owned by L Catterton, a consumer-focused private equity firm backed by LVMH. However, that ownership is about to change permanently.
On August 4, 2026, Procter & Gamble (P&G) — the world’s largest consumer goods company — announced a definitive agreement to acquire Thorne for $3.8 billion. The deal is pending regulatory approval and customary closing conditions, with P&G targeting a close in the second quarter of fiscal year 2027. Until that regulatory process is complete, L Catterton remains the legal owner of Thorne.
Ownership and Key Stakeholders Table
| Owner / Party | Role | Stake | Key Detail |
|---|---|---|---|
| L Catterton | Current Owner (pending acquisition close) | 100% via Flagship Fund | LVMH-backed PE firm; took Thorne private in 2023 for $680 million |
| Procter & Gamble (NYSE: PG) | Pending Acquirer | Will own 100% post-close | Announced $3.8B deal on August 4, 2026; close expected Q2 FY2027 |
| Thorne HealthTech, Inc. | Operating Company | Was publicly traded (NASDAQ: THRN) | Went public in 2021 at $525M; taken private by L Catterton in 2023 |
| Public Shareholders (historical) | Former shareholders | Fully bought out in 2023 | Thorne delisted from NASDAQ after L Catterton tender offer |
| NSF International | Certifying Body | No equity | Certifies Thorne products as NSF Certified for Sport — key trust signal |
The Origin Story: Founded in 1984 on a Simple Principle
Thorne was founded in 1984 with a principle that was radical for its time: supplements should be made without unnecessary fillers, artificial additives, or ingredients that compromise absorption. At a time when the supplement industry had almost no regulatory oversight and very little quality control, Thorne positioned itself as the brand that healthcare practitioners could actually trust.
The company built its reputation slowly and deliberately — starting in the practitioner channel, meaning it sold primarily to doctors, naturopaths, and nutritionists who then recommended products to their patients.
That approach meant Thorne never needed to shout to be heard. It built loyalty through clinical credibility rather than marketing spend — and that foundation of trust became its most valuable asset.
Thorne also made the rare decision to manufacture all of its products in its own facility in South Carolina — a vertically integrated model that gives it complete control over ingredient quality, testing, and production standards. Most supplement brands outsource manufacturing. Thorne never has.
The Road to L Catterton: IPO, Then Private Again
Thorne’s ownership history in recent years has moved fast. The company went public on the NASDAQ in late 2021 under the ticker THRN at a valuation of approximately $525 million. The IPO was intended to fuel expansion — into direct-to-consumer channels, sports performance partnerships, and personalized health testing.
But the public markets were not kind to consumer health brands in 2022 and early 2023, and Thorne’s stock struggled to reflect what the company believed was its true value.
In August 2023, L Catterton — the same LVMH-backed private equity firm that now also has a stake in HYROX — launched a tender offer to take Thorne private. The deal valued the company at $680 million — a 30% premium over where the stock had been trading.
L Catterton then spent the following two years accelerating Thorne’s growth, helping the brand expand its retail presence, build out its sports performance partnerships, and push annual revenue past $500 million in 2025.
That revenue milestone — combined with L Catterton’s aggressive brand-building — is exactly what made Thorne attractive enough for P&G to pay $3.8 billion for it. That is almost a sixfold increase from the $680 million take-private valuation in just three years — delivering L Catterton an extraordinary 77% rate of return on its investment.
The $3.8 Billion P&G Deal: What It Means
The announcement on August 4, 2026 sent shockwaves through the supplement industry. Procter & Gamble CEO Shailesh Jejurikar told CNBC’s Sara Eisen: “We are really happy with the asset itself. It’s a really well-run operation, and it’s been around for a long time.”
P&G already owns several supplement and healthcare brands — including Metamucil, Align Probiotic, New Chapter vitamins, Vicks, and Oral-B. Thorne will sit within P&G’s Personal Health Care division alongside those brands, giving P&G a premium, science-backed, practitioner-trusted anchor in the fast-growing vitamins, minerals, and supplements category.
For many loyal Thorne customers, the reaction was mixed. P&G is the definition of mass-market consumer goods — and Thorne has built its entire identity on being the opposite of that.
But industry analysts pointed to P&G’s handling of New Chapter — a premium supplement brand it acquired in 2012 that has remained quality-focused under corporate ownership — as a reason for cautious optimism. Thorne has publicly committed in its press release that there will be no changes to formulations, manufacturing standards, or third-party certifications.
What Does Thorne’s Future Look Like Under P&G?
The deal has not yet closed — P&G is targeting close in the second quarter of fiscal year 2027, subject to regulatory approval. Until then, L Catterton remains the owner and Thorne continues to operate independently.
Once the deal closes, Thorne will gain access to P&G’s global distribution network — one of the most powerful in the world — which could dramatically expand the brand’s reach into international markets where it currently has limited presence. P&G’s marketing resources, retail relationships, and research capabilities could accelerate product development. The key question the supplement industry is watching closely is whether Thorne’s premium positioning, clinical credibility, and practitioner-channel trust can survive inside one of the world’s largest consumer goods corporations.
The Bottom Line
Frequently Asked Questions (FAQs)
Q1. Who owns Thorne supplements in 2026?
Thorne is currently owned by L Catterton, an LVMH-backed private equity firm, pending its $3.8 billion acquisition by Procter & Gamble announced on August 4, 2026.
Q2. Is Procter & Gamble buying Thorne?
Yes. P&G announced a definitive agreement to acquire Thorne for $3.8 billion on August 4, 2026, with the deal expected to close in Q2 FY2027 pending regulatory approval.
Q3. When did L Catterton buy Thorne?
L Catterton took Thorne private in August 2023 via a tender offer valuing the company at $680 million, buying it out from NASDAQ public shareholders.
Q4. Was Thorne ever publicly traded?
Yes. Thorne went public on the NASDAQ under the ticker THRN in late 2021 at a valuation of approximately $525 million before being taken private in 2023.
Q5. When was Thorne founded?
Thorne was founded in 1984, making it one of the oldest premium supplement brands in the United States, with over 42 years of continuous operation.
Q6. How much revenue does Thorne generate?
Thorne’s annual revenue surpassed $500 million in 2025, a key milestone that helped justify P&G’s $3.8 billion acquisition price.
Q7. Will the P&G acquisition change Thorne’s formulas?
Thorne has publicly stated that no changes to formulations, manufacturing standards, or third-party certifications — including its NSF Certified for Sport status — are planned following the acquisition.
Q8. What other brands does P&G own alongside Thorne?
P&G owns Metamucil, Align Probiotic, New Chapter vitamins, Vicks, Oral-B, and Crest — Thorne will join this healthcare portfolio upon deal close.
Thorne is currently owned by L Catterton — the LVMH-backed private equity firm that took the company private in 2023 for $680 million.
On August 4, 2026, Procter & Gamble announced a definitive agreement to acquire Thorne for $3.8 billion — nearly six times the 2023 take-private valuation — with closing expected in Q2 FY2027 pending regulatory approval.
Founded in 1984 on a commitment to ingredient purity and practitioner trust, Thorne has grown from a quiet supplement brand in the healthcare channel to a $500 million+ revenue company trusted by professional athletes, 100+ sports teams, and tens of thousands of healthcare professionals worldwide.
Whatever happens under P&G ownership, the brand’s 42-year foundation of scientific credibility will be its most valuable — and most carefully watched — asset going forward.